NCT04991311View on ClinicalTrials.gov

The Long-term Effect on Intestinal Absorption and Safety of Treatment With Glepaglutide in Patients With Short Bowel Syndrome

PHASE3CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

August 10, 2021

Primary Completion Date

February 2, 2023

Study Completion Date

September 5, 2023

Conditions
Short Bowel Syndrome
Interventions
DRUG

Glepaglutide

Glepaglutide will be delivered in a single-use autoinjector.

Trial Locations (1)

Unknown

Rigshospitalet, Copenhagen

Sponsors

Lead Sponsor

Zealand Pharma
All Listed Sponsors
lead

Zealand Pharma

INDUSTRY